JP2006504751A5 - - Google Patents

Download PDF

Info

Publication number
JP2006504751A5
JP2006504751A5 JP2004544592A JP2004544592A JP2006504751A5 JP 2006504751 A5 JP2006504751 A5 JP 2006504751A5 JP 2004544592 A JP2004544592 A JP 2004544592A JP 2004544592 A JP2004544592 A JP 2004544592A JP 2006504751 A5 JP2006504751 A5 JP 2006504751A5
Authority
JP
Japan
Prior art keywords
methyl
hydrogen
parathyroid
lower alkyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004544592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504751A (ja
JP4672368B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/004514 external-priority patent/WO2004035050A1/en
Publication of JP2006504751A publication Critical patent/JP2006504751A/ja
Publication of JP2006504751A5 publication Critical patent/JP2006504751A5/ja
Application granted granted Critical
Publication of JP4672368B2 publication Critical patent/JP4672368B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004544592A 2002-10-15 2003-10-13 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 Expired - Fee Related JP4672368B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
PCT/IB2003/004514 WO2004035050A1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism

Publications (3)

Publication Number Publication Date
JP2006504751A JP2006504751A (ja) 2006-02-09
JP2006504751A5 true JP2006504751A5 (enExample) 2006-11-30
JP4672368B2 JP4672368B2 (ja) 2011-04-20

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004544592A Expired - Fee Related JP4672368B2 (ja) 2002-10-15 2003-10-13 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用

Country Status (15)

Country Link
US (2) US20060142354A1 (enExample)
EP (1) EP1553938B1 (enExample)
JP (1) JP4672368B2 (enExample)
CN (1) CN1297269C (enExample)
AT (1) ATE350034T1 (enExample)
AU (1) AU2003267751A1 (enExample)
BR (1) BR0315293A (enExample)
CA (1) CA2501717C (enExample)
CY (1) CY1106385T1 (enExample)
DE (1) DE60310975T2 (enExample)
DK (1) DK1553938T3 (enExample)
ES (1) ES2279139T3 (enExample)
PT (1) PT1553938E (enExample)
SI (1) SI1553938T1 (enExample)
WO (1) WO2004035050A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2496477C (en) 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1155689E (pt) * 1993-07-19 2007-01-31 Angiotech Pharm Inc Composições anti-angiogenicas e metodos de utilização
WO1998022461A1 (de) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
KR20080016756A (ko) * 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Similar Documents

Publication Publication Date Title
JP2013501731A5 (enExample)
NZ527113A (en) Rapid-onset medicament for the treatment of sexual dysfunction
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
JP2010500376A5 (enExample)
RU2000113729A (ru) Гетероциклические соединения для ингибирования секреции желудочной кислоты, способы их получения и их фармацевтические компоозиции
JP2009504763A5 (enExample)
JP2006523216A5 (enExample)
WO2010081817A1 (en) Method for treating colorectal cancer
JP2006506443A5 (enExample)
JP2020507589A5 (enExample)
JP2006503850A5 (enExample)
JP2008520544A5 (ja) 癌関連疲労の治療または予防のための医薬の製造への使用方法
JP2006514092A5 (enExample)
JP2006507220A5 (enExample)
CA2671470A1 (en) Powder formulation for valganciclovir
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
RU2010123028A (ru) Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона
JP2003519228A5 (enExample)
JP2020532562A5 (enExample)
ES2405323T3 (es) Tratamiento de melanoma
JPH10147529A5 (enExample)
EP4447973A1 (en) Use of combination therapy for treating cancer
US20160287549A1 (en) Novel methods for treating neurodegenerative diseases
CN103327975A (zh) 用于治疗多形性成胶质母细胞瘤的含有马西替坦的组合物
JP2012525411A5 (enExample)